English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

CONCERT-1 (1) is an international, open-label, randomized, controlled, phase 2 trial, in which 150 patients with previously untreated stage III, IVa, or IVb, locally advanced (LA) non-nasopharyngeal squamous cell carcinoma of the head and neck (HNSCC) from 41 sites in 9 countries were randomly assigned 2:3 to open-label concurrent chemoradiotherapy (CCRT) (three cycles of cisplatin 100 mg/m 2 ) or panitumumab plus CCRT (three cycles of intravenous panitumumab 9.0 mg/kg every 3 weeks plus cisplatin 75 mg/m 2 ).

CONCERT-1, an additional piece in the puzzle of (bio)-(chemo)-radiation